PDCD1 and neoplasm: ALKBH5 has been employed in anti‐PD‐1 immunotherapy to regulate lactic acid levels in the tumor microenvironment (TME) and manage the accumulation of Tregs and myeloid‐derived suppressor cells (MDSCs).